- Home
- CYCU vs OSRH Comparison
CYCU vs OSRH Comparison
Compare CYCU & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCU
- OSRH
- Stock Information
- Founded
- CYCU N/A
- OSRH N/A
- Country
- CYCU United States
- OSRH United States
- Employees
- CYCU N/A
- OSRH N/A
- Industry
- CYCU
- OSRH
- Sector
- CYCU
- OSRH
- Exchange
- CYCU Nasdaq
- OSRH Nasdaq
- Market Cap
- CYCU 13.1M
- OSRH 11.1M
- IPO Year
- CYCU N/A
- OSRH N/A
- Fundamental
- Price
- CYCU $0.20
- OSRH $0.62
- Analyst Decision
- CYCU
- OSRH
- Analyst Count
- CYCU 0
- OSRH 0
- Target Price
- CYCU N/A
- OSRH N/A
- AVG Volume (30 Days)
- CYCU 36.4M
- OSRH 13.9M
- Earning Date
- CYCU 08-13-2025
- OSRH 08-14-2025
- Dividend Yield
- CYCU N/A
- OSRH N/A
- EPS Growth
- CYCU N/A
- OSRH N/A
- EPS
- CYCU N/A
- OSRH N/A
- Revenue
- CYCU $16,285,283.00
- OSRH $104,735.00
- Revenue This Year
- CYCU N/A
- OSRH N/A
- Revenue Next Year
- CYCU N/A
- OSRH N/A
- P/E Ratio
- CYCU N/A
- OSRH N/A
- Revenue Growth
- CYCU N/A
- OSRH N/A
- 52 Week Low
- CYCU $0.17
- OSRH $0.45
- 52 Week High
- CYCU $10.99
- OSRH $13.40
- Technical
- Relative Strength Index (RSI)
- CYCU N/A
- OSRH 45.01
- Support Level
- CYCU N/A
- OSRH $0.57
- Resistance Level
- CYCU N/A
- OSRH $0.62
- Average True Range (ATR)
- CYCU 0.00
- OSRH 0.10
- MACD
- CYCU 0.00
- OSRH 0.00
- Stochastic Oscillator
- CYCU 0.00
- OSRH 10.81
About CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.